Innovative Solutions for
Over 5.7 million people in the US and 20 million people worldwide suffer from heart failure. Nearly 45-54% of these patients suffer from Diastolic Heart Failure (DHF) and are without effective treatment. CorAssist is developing the first device focused on treating DHF patients.
Diastolic Heart Failure (DHF)
CorAssist is committed to developing innovative therapeutic products for treating DHF. The company's product, the CORolla™ is the first device to directly improve cardiac diastolic function, and can be implanted in Trans Apical or Percutaneous approach.
Diastolic dysfunction secondary to aortic stenosis undergoing AVR is not improving or just slightly improving post-surgery and their prognosis compared to patients undergoing AVR without diastolic dysfunction is worse. The CORolla may improve diastolic function in those patients as well.
The CORolla™ is an elastic self-expanding internal spring like device implanted inside the Left Ventricle (LV) through a minimally invasive (left thoracotomy) or percutaneous (trans catheter) procedure. The device applies direct expansion forces on the LV wall and the septum.
The company's first product, the ImCardia®, is the proof of concept of direct cardiac diastolic function improvement.